Grey
Brand Name(s):Evista
Indication:Primary prevention of osteoporotic fractures in postmenopausal women
Rationale:1
Considered:Oct-07
Review Date:Jan-26
Comments:
NICE TA160: Raloxifene is not recommended as a treatment option for the primary prevention of osteoporotic fragility fractures in postmenopausal women.